LEIDEN, Netherlands, Feb. 1, 2026 — Pharming Group announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja (leniolisib) in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). The FDA action relates to pediatric pharmacokinetic and analytical testing considerations and does not affect the drug’s existing approval for patients aged 12 years and older.

Science Significance

Joenja is an oral, selective PI3Kδ inhibitor designed to correct immune dysregulation in APDS, a rare and progressive primary immunodeficiency. The pediatric sNDA was supported by data from a Phase III open-label study demonstrating improvements in lymphadenopathy reduction and naïve B-cell restoration, two clinically relevant hallmarks of disease correction. The CRL highlights FDA concerns regarding potential underexposure in lower-weight pediatric patients, underscoring the scientific importance of age- and weight-appropriate pharmacokinetic modeling in rare pediatric populations. These findings reinforce the complexity of translating adult and adolescent dosing paradigms into younger pediatric cohorts while maintaining consistent therapeutic exposure.

Regulatory Significance

From a cGxP and .Clinical standpoint, the CRL represents a regulatory checkpoint rather than a rejection. The FDA requested additional pediatric pharmacokinetic data to confirm exposure comparability across weight bands, along with clarification related to one analytical method used in production batch testing. Such requests are common in pediatric label expansions, where clinical pharmacology and analytical validation are subject to heightened scrutiny. Pharming has indicated its intent to request a Type A meeting with the FDA, reflecting active regulatory engagement and a clear pathway toward resubmission under GCP and CMC expectations.

Business Significance

While the CRL delays potential market expansion, it does not diminish the long-term commercial value of Joenja. The therapy remains the first and only targeted treatment approved for APDS in patients aged 12 years and older in multiple markets. Addressing FDA feedback through additional data generation may ultimately strengthen the product label and clinical confidence in pediatric use. From a strategic perspective, resolving dosing and analytical issues is critical for unlocking future growth in rare pediatric immunology, a segment characterized by high unmet need and strong reimbursement fundamentals.

Patients’ Significance

For families affected by APDS, the FDA decision is a temporary setback but not a termination of progress. Currently, no targeted therapies are approved globally for children under 12 years with this condition. Joenja has shown the ability to correct underlying immune dysfunction, rather than merely managing symptoms, offering hope for improved long-term outcomes. Ensuring appropriate dosing for younger, lower-weight children is essential to balancing safety, efficacy, and durability of response, reinforcing the FDA’s patient-protection mandate. Pharming has reiterated its commitment to making the therapy available to this underserved population.

Policy Significance

The CRL highlights broader policy challenges in pediatric rare-disease drug development, where small patient populations, ethical considerations, and dosing variability complicate regulatory decision-making. FDA emphasis on pediatric pharmacokinetics and analytical robustness aligns with evolving regulatory frameworks that prioritize evidence-based dosing precision. The case underscores the importance of early and iterative regulatory dialogue and may inform future guidance on pediatric extensions for targeted therapies in ultra-rare conditions.

The FDA’s Complete Response Letter for pediatric Joenja underscores the rigor of clinical and regulatory standards applied to pediatric label expansions, particularly in rare immunodeficiencies. While additional work is required, Pharming Group retains a clear regulatory pathway forward, supported by positive clinical efficacy and safety data. The development illustrates how .Clinical-focused regulatory feedback, grounded in GxP principles, ultimately serves to optimize therapeutic use and safeguard vulnerable patient populations as innovative medicines move toward broader access.

Source: Pharming Group press release